IBio (NYSEMKT:IBIO) announces that
immunization studies for its SARS-CoV-2 Virus-Like Particle program
(IBIO-200) are proceeding at Texas A&M University System
laboratories, closing in on clinical trials.
It says it created the candidates in just a few weeks utilizing its FastPharming System, a plant-based expression platform.
https://seekingalpha.com/news/3555409-ibio-up-29-premarket-on-advancement-of-coronavirus-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.